Drugs / FB-101
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07126704 | Nov 2025 → Jun 2026 overdue | — | 1ST Biotherapeutics, Inc. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT04165837 | Oct 2019 → Nov 2021 | Parkinson disease | 1ST Biotherapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FB-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07126704 ↗ |
| Route | Oral | “oral doses of FB-101” NCT04165837 ↗ |